Dermavant Sciences, Inc.: Dermavant to Present Data from Multiple Studies of VTAMA (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference

- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study

Related Keywords

United States ,Hawaii ,Americans ,Laurence Watts ,Christopherem Griffiths ,Holly Glover ,Stephenc Piscitelli ,Philipm Brown ,Kimberly Mchale ,Markg Lebwohl ,Aprilw Armstrong ,Shawng Kwatra ,Kima Papp ,Bruce Strober ,Rachaela Clark ,Scott Guenthner ,Matthewj Bruno ,Annam Tallman ,Robert Bissonnette ,Nathan Mooney ,Jennifer Cather ,Angela Salerno Robin ,Matthew Zirwas ,Amy Paller ,Ahmede Gehad ,Michael Cameron ,Kostenloser Wertpapierhandel ,Tomas Chao ,Jessicae Teague ,G Michael Lewitt ,Joshuaa Zeichner ,Davids Rubenstein ,Seemalr Desai ,Johne Jett ,Twitter ,Fairmont Orchid Hotel ,Drug Administration ,National Prescription Audit ,Dermavant Sciences Gmb ,Roivant Sciences ,Dermavant Sciences Inc ,Dermavant Sciences ,Linkedin Dermavant Sciences ,Annual Winter Clinical Dermatology Conference ,Grande Ballroom ,Tapinarof Cream ,Once Daily ,Extensive Atopic Dermatitis ,Week Maximal Use ,Rapid Improvements ,Two Phase ,Severe Plaque ,Leon Kircik ,Tapinarof Inhibits ,Cytokine Production ,Disease Control Off Treatment ,Minimal Disease Activity Through End ,Remittive Period ,Treat To Target Outcomes ,Treatment Success ,Three Phase ,Psoriasis Area Severity Index ,Exposure Response Analysis Demonstrates ,Local Effects ,James Del Rosso ,Plaque Psoriasis ,Clinical Efficacy ,Two Pivotal Phase ,Dermatology Life Quality Index ,Global Assessment ,Linda Stein Gold ,Prescribing Information ,Patient Information ,Prescription Audit ,Vice President ,Media Relations ,Dermavant ,Ciences ,Present ,Data ,Rom ,Multiple ,Studies ,Mtama ,Tapinarof ,Cream ,023 ,Winter ,Linical ,Ermatology ,Conference ,